Date of Abstract presentation12th December 2023IndicationsMultiple MyelomaAbstract NumberLBA1Abstract typeOral
The PERSEUS study is being conducted in collaboration with the European Myeloma Network as a sponsor. PERSEUS is an ongoing, randomized, open-label, Phase III study comparing the efficacy and safety of D-VRd followed by D-R maintenance vs VRd followed by R maintenance in patients with transplant-eligible NDMM. The findings presented at the ASH 2023 demonstrated that, at a median follow-up of 47.5 months, the 4-year progression-free survival (PFS) rate with D-VRd was 84.3% vs. 67.7% with VRd, resulting in a 58% reduction in the risk of disease progression o...
